The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival with circulating tumor DNA-guided therapy in advanced non-small cell lung cancer.
 
Justin Jee
Patents, Royalties, Other Intellectual Property - Patient license, MDSeq Inc
 
Emily S. Lebow
No Relationships to Disclose
 
Yonina R. Murciano-Goroff
Travel, Accommodations, Expenses - AstraZeneca
 
Gowtham Jayakumaran
No Relationships to Disclose
 
Ronglai Shen
Research Funding - GRAIL
 
Angela Rose Brannon
Stock and Other Ownership Interests - Johnson & Johnson
 
Ryma Benayed
Honoraria - Loxo
Research Funding - Archer
Travel, Accommodations, Expenses - Archer
Other Relationship - Illumina
 
Azadeh Namakydoust
Consulting or Advisory Role - Bayer
Travel, Accommodations, Expenses - Bayer
 
Michael Offin
Honoraria - OncLive
Consulting or Advisory Role - Jazz Pharmaceuticals; Novartis; PharmaMar; Targeted Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Paul K. Paik
Honoraria - AstraZeneca; Bicara Therapeutics; Boehringer Ingelheim; Calithera Biosciences; EMD Serono; GlaxoSmithKline; Takeda; Xencor
Consulting or Advisory Role - AstraZeneca; Bicara Therapeutics; Boehringer Ingelheim; Calithera Biosciences; EMD Serono; GlaxoSmithKline; Takeda; Xencor
Research Funding - Bicara Therapeutics; Boehringer Ingelheim; EMD Serono
 
Helena Alexandra Yu
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Janssen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Cullinan Oncology (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Astellas Pharma
 
Mark Donoghue
No Relationships to Disclose
 
Ahmet Zehir
Stock and Other Ownership Interests - Arcus Biosciences; Mirati Therapeutics
Honoraria - Illumina
 
Alexander E. Drilon
Honoraria - Foundation Medicine; Medscape; MORE Health; OncLive; Peerview; PeerVoice; Physicans' Education Resource; Research to Practice; Targeted Oncology
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Archer; AstraZeneca; Bayer; BeiGene; BerGenBio; Blueprint Medicines; EMD Serono/Merck; Exelixis; Genentech/Roche; Helsinn Therapeutics; Hengrui Therapeutics; Ignyta; Lilly; Loxo; Melendi; Monopteros Therapeutics; Monopteros Therapeutics; MORE Health; Novartis; Pfizer; Remedica; Repare Therapeutics; Takeda/Millennium; TP Therapeutics; Tyra Biosciences; Verastem; Verastem
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - GlaxoSmithKline; Merck; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
David B. Solit
Stock and Other Ownership Interests - Fore Biotherapeutics; Loxo; Scorpion Therapeutics; Vividion Therapeutics
Consulting or Advisory Role - BridgeBio Pharma; Illumina; Lilly; Pfizer; QED Therapeutics; Scorpion Therapeutics; Syros Pharmaceuticals; Vividion Therapeutics
 
David Randolph Jones
Stock and Other Ownership Interests - Diffusion Pharmaceuticals
Other Relationship - AstraZeneca; JuniperMD; Merck
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Amgen; Amgen; AstraZeneca; Bridge Medicines; Celgene; Earli; Epizyme; Genentech/Roche; Harpoon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Lilly; Syros Pharmaceuticals; Syros Pharmaceuticals
Research Funding - Merck (Inst); Roche/Genentech (Inst)
 
Michael F. Berger
Research Funding - Grail
Patents, Royalties, Other Intellectual Property - Provisional patent pending for "Systems and Methods for Detecting Cancer via cfDNA Screening"
 
James M. Isbell
Stock and Other Ownership Interests - LumaCyte
(OPTIONAL) Uncompensated Relationships - Genentech
 
Bob T. Li
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); GRAIL (Inst); Guardant Health (Inst); Hengrui Therapeutics (Inst); Lilly (Inst); MORE Health (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Karger Publishers - Book royalty; Shanghai Jiao Tong University Press - Book royalty; US62/514,661 (Inst); US62/685,057 (Inst)
Travel, Accommodations, Expenses - Jiangsu Hengrui Medicine; MORE Health
(OPTIONAL) Uncompensated Relationships - Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Genentech; Lilly